Abstract
The human luteinising hormone choriogonadotropin receptor (LHCGR) is a G-protein coupled receptor activated by both human chorionic gonadotropin (hCG) and luteinizing hormone (LH), two structurally related gonadotropins with essential roles in ovulation and maintenance of the corpus luteum. LHCGR expression predominates in ovarian tissues where it elicits functional responses through cyclic adenosine mononucleotide (cAMP), Ca2+ and extracellular signal-regulated kinase (ERK) signalling. LHCGR expression has also been localized to the human endometrium, with purported roles in decidualization and implantation. However, these observations are contentious. In this investigation, transcripts encoding LHCGR were undetectable in bulk RNA sequencing datasets from whole cycling endometrial tissue and cultured human endometrial stromal cells (EnSC). However, analysis of single-cell RNA sequencing data revealed cell-to-cell transcriptional heterogeneity, and we identified a small subpopulation of stromal cells with detectable LHCGR transcripts. In HEK-293 cells expressing recombinant LHCGR, both hCG and LH elicited robust cAMP, Ca2+ and ERK signals that were absent in wild-type HEK-293 cells. However, none of these responses were recapitulated in primary EnSC cultures. In addition, proliferation, viability and decidual transformation of EnSC were refractory to both hCG and LH, irrespective of treatment to induce differentiation. Although we challenge the assertion that LHCGR is expressed at a functionally active level in the human endometrium, the discovery of a discrete subpopulation of EnSC that express LHCGR transcripts may plausibly account for the conflicting evidence in the literature.
Similar content being viewed by others
Introduction
Human chorionic gonadotropin (hCG) and luteinising hormone (LH), like all other gonadotropin hormones, are heterodimers consisting of two monomeric glycoproteins that combine to make a functional protein. They share a common α-subunit, with structural and functional specificity conferred through differing β-subunits. Despite structural similarities, hCG and LH exhibit different temporal profiles and distinct physiological roles1. In women, LH is produced and released by gonadotropic cells of the anterior pituitary gland, and surges during the mid-luteal phase of the menstrual cycle to drive ovulation and initiate the development of the corpus luteum, a temporary ovarian endocrine structure that produces progesterone. hCG, however, is secreted by trophoblast cells of early embryos and the placenta and plays a vital role in sustaining circulating progesterone during early pregnancy1,2.
Within the cycling endometrium, signals from the post-ovulatory rise in progesterone converge with local cyclic adenosine monophosphate (cAMP) production to drive a process of differentiation termed decidualization. This transforms endometrial stromal cells (EnSC) into specialized secretory decidual cells and marks the remodelling of endometrial tissue into the decidua of pregnancy, an immune privileged and nutritive matrix that supports embryo implantation and development3. However, reprogrammed EnSC can also emerge as acute progesterone-independent senescent decidual cells, which propagate within the tissue via inflammatory paracrine secretions and secondary senescence4,5. Thus, as progesterone levels fall in the late luteal phase of a non-conception cycle, the decidual tissue is consumed by sterile inflammation and cellular senescence before eventual breakdown and shedding through menstruation4,5,6. However, progesterone-dependent decidual cells secrete chemo-attractants to recruit and activate uterine natural killer (uNK) cells, the dominant leukocyte population in the endometrium, which then target and eliminate senescent cells through exocytosis and limit the propagation of senescence in a conception cycle4,5. Sustained progesterone signalling is thus essential in maintaining the decidua of pregnancy, and it is embryo-derived hCG that prevents programmed atrophy of the corpus luteum to maintain ovarian progesterone production in a conception cycle. This represents an inflection point in the menstrual cycle whereby the fate of the endometrium is principally dependent upon the selection and implantation of embryos that are capable of secreting sufficient hCG and other fitness hormones7,8,9,10.
Both hCG and LH act through the luteinising hormone choriogonadotrophin receptor (LHCGR), a 7-transmembrane G-protein coupled receptor (GPCR) comprising a large extracellular domain that binds hCG and LH1,11,12. Activated LHCGR couples to Gαs G-proteins to initiate the adenylyl cyclase, cAMP and protein kinase A (PKA) signalling pathway1,11. It also activates extracellular signal-regulated kinase (ERK) and protein kinase B (PKB/AKT) to drive cell proliferation, differentiation and survival in a variety of cell types1,13. In addition, at high hormone and receptor levels, LHCGR couples to Gαq G-proteins to activate phospholipase C and inositol phosphate signalling to increase intracellular Ca2+14,15.
Congruent with its role in ovulation and corpus luteum formation, LHCGR is prominently expressed in the ovaries11, but several studies reported extra-gonadal expression in tissues of the lower reproductive tract, including a variety endometrial cells16,17,18,19,20,21,22,23,24. However, these observations have been challenged25. Full-length LHCGR transcripts contain 11 exons and 10 introns, but several splice and truncated variants have been identified26,27. In one study, full-length LHCGR transcripts were absent in 3 out of 8 secretory phase endometrial biopsies and in 10 out of 12 decidua from early pregnancy17. They were also non-detectable in a further study except for a variant that lacks an extracellular domain28. In addition, many conclusions are derived from immunogenic assays, which are limited by the sensitivity and specificity of antibodies that target gonadotropin hormone receptors29.
The functional role of LHCGR in the endometrium is also controversial. For example, there is opposing evidence for hCG-mediated generation of intracellular cAMP18,22,23,30,31,32, for the role of LHCGR in decidual prolactin production16,30,32,33, and whether expression and function are cycle-dependent17,19,21,22,32.
In the present study, we mined publicly available RNA sequencing data. Transcript for LHCGR were either low or undetectable in bulk sequencing datasets from whole endometrial biopsies and cultured primary endometrial stromal cells (EnSC) but were identified in a discrete sub-set of EnSC from single-cell RNA-sequencing datasets. However, primary EnSC cultures were non-responsive to hCG and LH.
Results
Lack of LHCGR transcripts in the endometrium
A summary of the literature pertaining LHCGR expression in endometrial cells is shown in Table 1. To explore LHCGR expression in endometrium, we mined publicly available RNA-sequencing (RNA-seq) data from whole endometrial biopsies and primary EnSC cultures (GEO accession numbers: GSE65102 and GSE104721). In whole tissues, transcripts encoding LHCGR were rare or undetectable. Average levels were 0.15 ± 0.26 (mean ± SD) transcripts per million (TPM) and significantly lower (P < 0.05) than those encoding other GPCRs implicated in endometrial regulation, including the prostaglandin E2 (PGE2) receptor (PTGER2), relaxin family peptide receptor-1 (RXFP1) and the lysophosphatidic acid receptor (LPAR1) (Fig. 1a). Equally, in EnSC, LHCGR transcripts were rare or absent, whereas those encoding other GPCRs including PTGER2, RXFP1, LPAR1 and the oxytocin receptor (OXTR), were expressed prominently (Fig. 1b). For functional comparison, EnSC were challenge with 10 nM hCG, 1 µM PGE2 or 1 µM Relaxin-2 for 5 min to assess activation of Gαs-coupled LHCGR, prostanoid EP2 (PTGER2) and relaxin family peptide receptor 1 (RFXP1) receptors, respectively. The relative levels of cAMP mirrored those of receptor transcripts, with LHCGR unable to raise intracellular levels above basal (Fig. 1c). The use of comparator GPCRs provides perspective on the low level of LHCGR transcripts, and although each receptor will have a unique activation and regulation signature, there was a strong correlation between transcript expression and functional responses.
One disadvantage of bulk RNA-sequencing is that it masks subpopulation variability and heterogeneity between cells. Single-cell RNA sequencing (scRNA-seq) enables molecular characterisation of individual cells, and is a powerful tool to overcome these limitations by revealing heterogeneity within cell populations34. We therefore mined scRNA-seq data (GEO accession number: GSE127918) that reconstructed the decidual pathway by treating EnSC with 8-bromo-cAMP (cAMP) and the progestin medroxyprogesterone (MPA) over 8 days. Cells clustered into distinct cell states based on their transcriptional profiles in a time-dependent manner (Supplementary Fig. S1). Irrespective of cell state, the average expression of LHCGR transcripts was low when compared to RXFP1, LPAR1 or OXTR. One notable observation was the considerable transcriptional heterogeneity within EnSC for all receptors, including LHCGR (Fig. 1d). Out of the 4574 cells in the dataset we identified a discrete population of 97 (2.1%) cells where transcripts encoding LHCGR were detected (Fig. 1e). In addition, the major cell types within whole endometrial biopsies (GEO accession number: GSE127918) were deconvolved and identified based on their transcriptomic profile (Supplementary Fig. S1), and consistent with EnSC, LHCGR transcripts were detected in a subpopulation of stromal and epithelial cells (Supplementary Fig. S1). To further substantiate the heterogeneity in whole tissue we mined independent single cell transcriptomic data35, and again observed LHCGR transcripts in a small population of stromal cells (Supplementary Fig. S2).
hCG and LH preparations are bioactive
Previous studies on the responsiveness of endometrial cells to LH and hCG are contentious, as summarized in Table 2. Figure 2a depicts how active LHCGR couples to Gαs G-proteins and activates adenylate cyclase to increase intracellular cAMP, but the receptor can also trigger Ca2+ release and activate kinase pathways including ERK. To validate gonadotropin bioactivity, these key signalling pathways were investigated in HEK-293 cells recombinantly expressing LHCGR (HEK-LHCGR). Cells were challenged with either hCG or LH and compared to parallel experiments in wild-type HEK-293 cells (HEK-WT). Robust increases in intracellular cAMP were detected in HEK-LHCGR cells challenged for 5 min with either hCG or LH. Inductions were concentration-dependent and generated pEC50 values of − 9.671 (213 pM) for hCG and − 9.370 (426 pM) for LH, with maximal responses achieved at ~ 10 nM (Fig. 2b). By contrast, HEK-WT cells did not respond. HEK cells were also loaded with the Ca2+ sensitive dye Calbryte-520 and challenged with high concentrations of hCG or LH (1 µM). Both agonists elicited robust Ca2+ responses in HEK-LHCGR cells, but not HEK-WT cells (Fig. 2c). Further, a robust and sustained induction of phosphorylated (active)-ERK was detected with both ligands in HEK-LHCGR, whereas HEK-WT cells did not respond (Fig. 2d).
In addition to LHCGR, LH and hCG also bind with mannose and other C-type lectin receptors36,37,38,39. Significantly, hCG-mediated mannose receptor activation has been shown to induce uNK cell proliferation38. To demonstrate alternative hCG-receptor interactions, and to provide further evidence of bioactivity, we investigated the proliferative effects of hCG on uNK cells isolated from non-pregnant endometrial biopsies. We demonstrated previously that these uNK cells are viable, and stain positively for both the pan-leukocyte marker CD45 and the uNK specific marker CD569. In this study, uNK cell proliferation, as quantified by XTT assay, was augmented by 133 ± 35% (P = 0.0093) (mean ± SD) after 2 days in culture with 10 nM hCG. The overall number of uNK cells, as determined via haemocytometer, also increased by 202 ± 54% (P = 0.030) when cultured with hCG (Fig. 2e). These observations prompted us to characterize the expression profiles of mannose receptors within the endometrium. First, we mined publicly available RNA-seq data from endometrial biopsies (GEO accession number: GSE65102) and found that transcripts for both the mannose receptor C-type 1 (MRC1) and type 2 (MRC2) were abundant, and ~ 48 (P < 0.0001) and ~ 443 (P < 0.0001) fold higher than those for LHCGR, respectively (Supplementary Fig. S2). Next, we examined expression in EnSC (GEO accession number: GSE104721) and in isolated uNK cells (GEO accession number: GSE159288) and observed high levels of transcripts for MRC2, low levels for LHCGR and none for MRC1 (Supplementary Fig. S2). Likewise, MRC1 transcripts were absent within our whole tissue scRNA-seq data (GEO accession number: GSE127918), whereas MRC2 transcripts were abundantly expressed in the stromal compartment and immune cells, including lymphocytes (Supplementary Fig. S2). Similar observations from independent scRNA-seq data also indicated an absence of MRC1 transcripts in most cell types except a small population of macrophages, but widespread MRC2 expression in stromal and immune cells (Supplementary Fig. S2). Interestingly, for all receptors there was conspicuous heterogeneity between individual cells.
EnSC do not respond to hCG or LH
We next sought to investigate hCG and LH-mediated signalling in EnSC. In contrast to responses in HEK-LHCGR, neither hCG nor LH increased intracellular cAMP in primary EnSC cultures. Cells were however responsive to PGE2 (P = 0.037), known to activate Gαs-coupled EP2/EP4 prostanoid receptors, and forskolin (P < 0.0001), the receptor-independent adenylate cyclase activator (Fig. 3a). Further, the same concentration of hCG and LH (1 µM) that elicited robust Ca2+ responses in HEK-LHCGR cells failed to increase intracellular Ca2+ in EnSC, despite strong responses to PGE2, likely activating the Gαq/11-coupled EP1/EP3 prostanoid receptors (Fig. 3b). Likewise, basal levels of phosphorylated-ERK in both undifferentiated EnSC and those decidualized for 8 days were unchanged following stimulation with either hCG or LH (Fig. 3c).
Lack of functional LHCGR effects in EnSC
hCG inhibits proliferation in EnSC but also protects against stress-induced apoptosis33,40,41. Anti-apoptotic effects are also observed in ovarian cells, but conversely here LHCGR activation is pro-proliferative1. To screen for these key physiological responses, EnSC were grown on microelectronic sensors (xCELLigence) to permit real-time monitoring of cultures using electrical impedance to represent changes in cell shape and confluency. EnSC cultures exhibited a bi-phasic pattern of growth that stabilized into linear and sustained proliferation after 2 days. Neither the pattern, magnitude, nor rate of proliferation were affected by hCG or LH, even at high concentrations (1 µM) (Fig. 4a). Similarly, no differences in impedance were observed with hCG or LH during continuous monitoring of EnSC as they decidualized (C + M treatment) for 8 days (Fig. 4b). Furthermore, there were no differences in cell viability and proliferation, as measured by XTT assay, after 2-day culture with either ligand, even up to concentrations of 10 µM (Fig. 4c). The emergence of cellular senescence in a subpopulation of stromal cells is a key characteristic of decidualization4,5. We therefore investigated whether LH or hCG effected the induction of senescence-associated β-Galactosidase (SA-β-Gal), a key biomarker of cellular senescence. As expected, levels of SA-β-Gal in 8 day-decidualized EnSC cultures increased 1.83 ± 0.33-fold (mean ± SD) compared to untreated cultures. However, neither hCG (1.80 ± 0.19) nor LH (1.73 ± 0.23) impacted on SA-β-Gal activity (Fig. 4d).
Several studies propose a role for LHCGR in decidualization (see Table 2). Thus, we investigated whether hCG and LH regulate the induction and secretion of key decidual markers. As depicted in Fig. 5a, the expression of canonical decidual markers PRL and IGFBP1 co-insides with the emergence of markers that differentiate senescent and decidual cells. IL1RL1 is a specific biomarker of decidual cells and encodes both the transmembrane (ST2L) and soluble (sST2) interleukin 1 receptor like-1, an anti-inflammatory decoy receptor that sequesters IL-33. CLU on the other hand codes the molecular chaperone protein clusterin (apolipoprotein J) and is enriched within the senescent subpopulation4. First, since convergence of sustained cAMP and progesterone signalling is essential for decidualization3, we treated EnSC continuously for 8 days with MPA in combination with hCG or LH. In keeping with an absence of an acute rise in cAMP levels, sustained activation of LHCGR had no impact on either the induction of decidual markers (PRL and IGFBP1) or the emergence of decidual subpopulations (IL1RL1 and CLU) (Fig. 5b). To further investigate the role of LHCGR in EnSC differentiation, cultures from 9 individual patients were decidualized with for 8 days in combination with hCG or LH. Both the average basal and induced levels of decidual genes were refractory to hCG and LH (Fig. 5c), however considerable variability between cultures was observed for all genes. In addition, we found no significant changes in secreted levels of prolactin, IGFBP1, clusterin or sST2 when cells were decidualized for 8 days in the continued presence of LHCGR ligands (Fig. 5d).
Discussion
hCG secretions from early embryos indirectly influence the endometrium by preventing atrophy of the corpus luteum, thereby sustaining circulating progesterone and maintaining the decidua of pregnancy3. The direct effects of hCG however, are poorly understood. When hCG is flushed through the human or baboon uterus, changes in endometrial gene expression associated with implantation and decidualisation are observed, including upregulation of PRL, IGFBP1, leukaemia inhibitory factor (LIF), MMPs and IL-642,43. Although this suggests hCG-dependent activation of the LHCGR is important at the embryo-endometrial interface, attempts at recapitulating these observations in EnSC are contentious. Here, we sought to elucidate the responsiveness of EnSC to LHCGR ligands but failed to detect activation of key signal pathways or functional cellular responses. However, we identified for the first time, a subpopulation of stromal cells that do express LHCGR transcripts, and which may plausibly contribute to the discord between studies.
Although defining a threshold where genes can be considered functionally active poses a challenge for the analysis of transcriptomic sequencing data, there is a consensus that genes with TPM < 2 are unlikely to be actively transcribed44,45,46. Mean values for LHCGR transcripts in whole endometrial tissues were 0.15 TPM and should therefore be considered non-expressed. However, insight from scRNA-seq data highlights heterogeneity in LHCGR expression, and the identification of a subpopulation of EnSC with detectable LHCGR transcripts. Unfortunately, LHCGR expressing cells did not cluster as a distinct population, and thus comparative profiling with non-expressing cells was not performed. Similar cellular heterogeneity for other GPCRs does trigger cell-specific responses to inflammatory cues in vascular and inflammatory cells47,48, but our current understanding of GPCR heterogeneity in the endometrium is rudimentary, and whether LHCGR-positive cells are relevant in pathological conditions such as infertility, miscarriage and endometriosis awaits elucidation. The responsiveness of our primary EnSC to deciduogenic stimulus in the presence of hCG or LH varied markedly between cultures, and differential expression profiles may be a key factor in the diversity of responses that we, and others, observe.
The functional analysis of LHCGR is further complicated by the complex levels of regulation that govern its expression and function49. For example, several splice variants including non-functional receptors have been identified26,27,28, as have immature and constitutively active receptors11,50,51, plasma membrane clusters50,52,53,54, follicular stimulating hormone receptor (FSHR) heterodimers55,56, and receptor density-dependent signalling57,58,59. Fluctuations in expression and G-protein coupling have also been linked to circadian rhythms60. In addition, LHCGR is known to undergo rapid but transient agonist-mediated down-regulation via a LHCGR binding protein (LRBP) that accelerates the degradation of receptor mRNA61,62,63. Further, like many other GPCRs, the LHCGR undergoes desensitisation and internalisation upon activation that not only regulates G protein signalling, but also activates additional signalling pathways64,65. The consequences of these splice variants and regulatory mechanisms is poorly understood, and may impact profoundly on the expression and function of the receptor.
Unlike LH, CG is an evolutionarily newer protein arising from a gene duplication event of the LHβ gene and is unique to primates66,67. Both covalently bind carbohydrates, but hCG has more moieties on the β subunit creating a wider variety of potential glycoforms. Indeed, LH and hCG differentially activate the LHCGR to drive distinct biological activities1,68. The glycosylation status of hCG is likely to be heterologous and will change depending on the source of hCG and stage of pregnancy, such as the hyperglycosylated variant that predominates in early pregnancy2,69,70. Commercially available formulations are purified by a variety of methods and differ in their source and biological composition. Consequently, variations in glycosylation patterns between preparations are observed that differentially activate LHCGR and display unique biological activity69,71,72,73,74. While not addressed directly in this study, as neither LH nor hCG forms employed induced functional responses, the source and glycosylation status of gonadotropins should be considered when interpreting and comparing experimental observations.
The role of glycosylation is complicated further by non-LHCGR mediated effects through mannose and other lectin-like receptors. These receptors recognize terminal mannose, N-GlcNAc and fructose residues on glycans attached to proteins and are known to interact with pituitary hormones include TSH and LH36,37,38. They are abundant in a range of immune cells, many of which, including uNK cells, macrophages, dendritic cells, and regulatory T cells, infiltrate the maternal decidua. In this study, hCG augmented uNK cell proliferation, a response linked previously to activation of mannose receptors38. There is also further evidence that hCG stimulates cytokine release from peripheral blood mononuclear cells (PBMC), including IL-18, IL-1β, IL-6, and TNF-α, interferon γ and soluble IL-2 receptor36,75,76,77. In many cases, responses were sensitive to excess D-mannose and refractory to deglycosylated hCG, emphasising the importance of glyco-conjugates. Given the critical function of uNK cells and cytokine release during decidualisation and implantation4,5, immune cell/lectin receptor activation cannot be excluded from the endometrial responses to uterine hCG flushing. Here, we showed that stromal and immune cells predominantly express the type 2 mannose receptor (MRC2), whereas the LHCGR was mostly absent. It is therefore necessary for researchers to design future experiments that deplete cells of LHCGR and mannose receptors to identify receptor activation.
In an evolutionary context, hCG is no longer considered a useful signal of embryo fitness78. Considering the excessive production in early pregnancy, its extended half-life and multiple glycoforms, the role of hCG-mediated activation of the LHCGR in the endometrium, at least from the evolutionary perspective of embryo selection, may have become redundant. However, the endometrium undergoes profound adaptations during pregnancy in response to embryonic and environmental cues3. How the activation and regulation of endometrial LHCGR is modified during pregnancy, especially in response to embryonic hCG, is poorly understood, and highlights the need for models that recapitulate the multicellular endometrial environment during early pregnancy.
In summary, we report that transcripts for LHCGR were largely absent in non-pregnant endometrial tissues and EnSC cultures but were identified in a small subpopulation of stromal cells. Both hCG and LH failed to activate key signalling cascades and functional responses in primary EnSC. Our findings, highlights the need for caution when interpreting data that ignores both heterogeneity within endometrial cell populations and non-canonical hCG-LHCGR signalling through mannose and C-type lectin receptors.
Methods
In silico analysis
Receptor expression data were derived from in silico analysis of RNA sequencing data within the Gene Expression Omnibus (GEO) repository. Expression from bulk RNA-sequencing within secretory phase whole endometrial biopsies was derived from GEO accession number GSE6510279, in undifferentiated EnSC and cells decidualized for 4 days from GSE10472180, and in isolated uNK cells from GSE15926681. To determine receptor expression within individual cells we analysed single-cell RNA-sequencing (scRNA-seq) data from whole endometrial biopsies obtained 8 and 10 days following the pre-ovulation LH surge, and from EnSC cultures decidualized for 8 days (GSE127918)4. Single cell expression within endometrial tissues was also derived from an independent data set35, which was visualized using Cellxgene, a web-based interface for viewing single-cell transcriptomic data82.
Endometrial biopsy collection
Ethical approval and consent: Endometrial biopsies were obtained from women attending the Implantation Research Clinic at the University Hospitals Coventry and Warwickshire National Health Service Trust. The collection of endometrial biopsies for research was approved by the NHS National Research Ethics—Hammersmith and Queen Charlotte's & Chelsea Research Ethics Committee (REC reference: 1997/5065) and Tommy’s National Reproductive Health Biobank (REC reference: 18/WA/0356). Written informed consent was obtained prior to tissue collection in accordance with the Declaration of Helsinki, 2000. Endometrial sampling: Endometrial biopsies were collected 6–10 days after the pre-ovulatory LH surge using a Wallach Endocell™ Endometrial Cell Sampler and were processed immediately. A total of 40 biopsies were used for this investigation and patient demographics are shown in Supplementary Table S1. EnSC dissociation and culture: EnSC were isolated from fresh biopsies using methods described previously83. In summary, cells were dissociated by mincing and enzymatic digestion of the extracellular matrix using 500 µg/ml collagenase type 1a (Merck Life Sciences UK Ltd) and 100 µg/ml DNAse I (Lorne Laboratories Ltd, Reading, U.K) for 1 h at 37 °C. Glandular clumps and debris were removed by passing digested tissue through a 40 µM cell strainer before centrifugation (400×g, 5 min). Pellets were re-suspended and cultured in DMEM/F12 media supplemented with 10% dextran-coated charcoal stripped Foetal Bovine Serum (DCC-FBS), antibiotic–antimycotic solution (10 U/ml penicillin, 10 µg/ml streptomycin and 0.25 µg/ml Amphotericin B (Thermo Fisher Scientific)), 2 mM l-glutamine, 1 nM E2 and 2 mg/ml insulin at 37 °C in a 5% CO2, humidified environment. Growth media was refreshed within 18 h to remove non-adherent cells, including immune cells, red blood cells and cellular debris. uNK cells were isolated from this supernatant as required (see below). For passage and seeding, EnSC were lifted with 0.25% trypsin, and all treatment/stimulation protocols were performed in phenol-free DMEM/F‐12 media culture containing 2% DCC‐FBS and antibiotics/antimycotics. Cell treatment: To induce differentiation, EnSC were decidualized with 0.5 mM 8‐bromo‐cAMP (cAMP) and 10 µM medroxyprogesterone acetate (MPA) (C + M treatment) as required for individual experiments. Cell were treated with hCG and LH using concentrations and protocols required for individual experiments.
hCG and LH preparations
Urinary hCG was obtained from Merck Life Sciences UK Ltd (#CG10) (Gillingham, U.K), with an activity of 16 IU/mg. At a concentration of 10 nM, this activity equates to 5.82 IU/ml. Human LH was supplied by A.F. Parlow, from the National Hormone and Peptide Program, Harbor-UCLA Medical Center. LH activity was 6100 IU/mg, and 10 nM equates to 1.59 IU/ml.
HEK-293 cell culture
FLAG-human LHCGR plasmids were constructed and stably transfected into Human Embryonic Kidney (HEK)-293 cells as described previously84. HEK-LHCGR cells were maintained in DMEM supplemented with 10% DCC-FBS, 1% penicillin/streptomycin and 400 µg/ml Geneticin at 37 °C in a 5% CO2, humidified environment. Geneticin was excluded from wild-type HEK (HEK-WT) cells. HEK cells were passaged using 0.05% trypsin (< 1 min) and seeded into wells pre-coated with 50 µg/ml poly-d-lysine to aid adherence. Prior to assay, cells were downregulated in serum-free media for 18–24 h.
cAMP assay
Changes in cellular cAMP levels were determined using a modified 2-step High-Throughput Time Resolved Fluorescence (HTRF) cAMP kit (Cisbio Bioassay, Codolet, France). Confluent HEK or EnSC cultures in 6-well plates were down-regulated prior to stimulation and washed and assayed in Krebs–Henseleit Buffer (KHB) (composition: NaCl: 118 mM, d-glucose: 11.7 mM, MgSO4·7H2O: 1.2 mM; KH2PO4 1.2 mM, KCl 4.7 mM, HEPES 10 mM, CaCl2·2H2O: 1.3 mM, pH 7.4, 37 °C), containing 300 µM IBMX. Cells were challenged with hCG or LH (or appropriate controls) for 5 min at 37 °C and lysed by rapid aspiration of buffer and immediate addition of 50 µl ice-cold lysis buffer. Cell lysates were collected from wells and cAMP determined on a PHERAstar FS plate reader (BMG Labtech Ltd, Ortenberg, Germany) as per manufacturer’s instructions.
Ca2+ assay
HEK or EnSC cultures were seeded onto 35 mm glass-bottomed culture dishes (MatTek Corporation, MA, USA) and grown until ~ 80% confluent. Cells were down-regulated overnight, washed in KHB and loaded with 10 µM Calbryte™ 520 AM (Cal-520) (Stratech Scientific Ltd, Ely, U.K.), a Ca2+ sensitive fluorescent dye, for 1 h at 37 °C in a 5% CO2 humidified environment. Cal-520 was removed prior to assay for 15 min to allow de-esterification of AM esters. Dishes were mounted onto the stage of a µManager-controlled Olympus IX-85 microscope and equilibrated at 37 °C in KHB before imaging. Cells were challenged with 1 µM hCG or LH by direct bath addition and Cal-520 fluorescence captured by a DC4100 LED stack and GFP filter set (ThorLabs, Newton, NJ, U.S.A.). Images were obtained using a Zyla sCMOS camera (Andor Technology Ltd, Belfast, U.K.) at a frequency of 1 Hz for up to 5 min. Videos were analysed in ImageJ where changes in cytosolic fluorescence were used as an index of intracellular Ca2+. Changes in fluorescence were related to fluorescence at time 0 s to give a fold increase of fluorescence/fluorescence at time 0 s (F/F0). Mean peak response data was obtained from 12 cells chosen at random from each independent primary culture.
Western blot
EnSC and HEK cultures were grown to ~ 80% confluency in 6-well plates and down-regulated for 24 h prior to assay. Where required, EnSC were decidualized for 8 days prior to assay. Cells were assayed in KHB at 37 °C and challenged with 10 nM hCG or LH for up to 45 min. Experiments were terminated by aspiration of buffer and rapid lysis in ice-cold RIPA buffer containing cOmplete mini protease inhibitors (Roche, Basel, Switzerland) and phosphatase inhibitor cocktail 2 (1:1000) (Merck Life Sciences U.K. Ltd). Cell debris was removed from lysates via centrifugation (10,000×g, 2 min, 4 °C). Samples were prepared in 25% (v:v) NuPage LDS × 4 sample buffer (Fisher Scientific, Loughborough, U.K.) and 100 nM DTT (Merck Life Sciences U.K. Ltd), and heated at 95 °C for 5 min. Proteins were separated using standard SDS-PAGE electrophoresis techniques on 10% acrylamide gels and transferred onto 0.45 μm nitrocellulose membranes (GE Healthcare, Amersham, U.K.) where non-specific binding was blocked by 5% (w:v) powdered milk in TBS-T (50 mM Tris, 150 mM NaCl, pH 7.4, 0.5% (v:v) Tween-20) for 1 h at RT. Membranes were probed with antibodies targeting phosphorylated-ERK (1:2000 in TBS-T, phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) Antibody #9101, Cell Signalling Technologies, MA, U.S.A.) overnight at 4 °C. Blots were washed clear of unbound antibody in TBS-T before addition of anti-rabbit-HRP secondary antibody (1:1000 in 5% milk/TBS-T; Agilent Technologies, CA, U.S.A.) for 1 h at RT. Blots were again washed, before visualization of immune-reactive bands using ECL reagent (GE Healthcare) and auto-radiography. Protein loading was controlled by uniform cell seeding but also verified by detection of total-ERK. Here, antibodies were stripped from blots by submersion in boiling water for 5 min and re-blocked in 5% milk/TBS-T. Blots were probed with antibodies targeting total-ERK (1:2000 in TBS-T, p44/42 MAPK (ERK1/2) Antibody #9102, Cell Signalling Technologies). The density of individual bands for phospho-ERK was determined using GeneTools gel analysis software (Syngene, Cambridge, U.K.), and expressed relative to levels of total-ERK.
XTT cell viability assay
EnSC were grown in 96-well plates and down-regulated for 24 h prior to a 2-day treatment with hCG or LH, both with and without C + M treatment to induce decidualization. The viability of EnSC after treatment was assessed using the CyQuant™ XTT cell viability assay (Fisher Scientific) as per manufacturer’s instructions.
uNK cell isolation and counting
uNK cells were isolated and cultured as described elsewhere5,83. Briefly, unattached cells from freshly digested endometrial biopsies were collected following overnight culture and red blood cells were depleted via Ficoll-Paque density medium centrifugation (400×g, 30 min, RT). Cell suspensions were pooled from 4–5 patients to increase yield and incubated with magnetic microbeads targeting the uNK specific antigen CD56 (#130-050-401, Miltenyi Biotec, Bergisch Gladbach, Germany) diluted 1:20 in wash buffer (1% BSA/PBS) for 15 min at 4 °C. CD56+ cells were isolated through magnetic activated cell sorting (MACS). Isolated uNK cells were cultured in DMEM/F12 media supplemented with 10% DCC-FBS, 1% antibiotic/antimycotic and 125 pg/ml recombinant IL-15, and never assayed beyond day 4. Cells were treated with 10 nM hCG for 48 h before cell viability and proliferation was quantified by XTT assay and cell counting using a Neubauer-improved haemocytometer.
xCELLigence
EnSC viability and proliferation was assessed in real-time using an xCELLigence® Real Time Cell Analysis (RTCA) DP instrument (ACEA Biosciences Inc, San Diego, CA, U.S.A.). EnSC were seeded in E-16 xCELLigence plates at a density of 10,000 cells/well and cultured for 24 h. Both undifferentiated and decidualizing cells (C + M treated) were monitored in the presence of hCG and LH with electrical impedance referenced to 0 shortly before initiation of treatment. Changes in impedance were captured and analysed using the RTCA Software v1.2 to reflect changes in cell adherence and proliferation and were expressed as the arbitrary unit ‘cell index’.
Senescence associated-β-galactosidase
Levels of the cellular senescence marker Senescence Associated-β-Galactosidase (SA-β-Gal) were determined using a modified version of the 96-well Quantitative Cellular Senescence Assay kit (Cell Biolabs Inc; CA, U.S.A.). Both undifferentiated and decidualizing (C + M treated) EnSC in 96-well plates were treated with 10 nM hCG or LH for 8 days, with media refreshed every 2 days. To determine levels of SA-β-Gal, cells were washed in ice-cold PBS and lysed in 50 μl ice-cold assay lysis buffer containing cOmplete™ mini protease inhibitors. Lysates (25 µl) were transferred to black-walled, black-bottomed 96-well plates where an equal volume of 2 × assay buffer was added as per manufacturer’s guidelines. Plates were sealed to avoid evaporation and the reaction incubated for 1 h at 37 °C in a non-humidified, non-CO2 incubator. The reaction was terminated by 200 μL stop solution and fluorescent intensity units (F.I.U.) were determined on a PHERAstar FS plate reader at 360/465 nm. Assays were normalized by identical cell seeding.
RT-qPCR
Total RNA from EnSC was extracted using STAT-60 (AMSBio, Abingdon, U.K.), according to manufacturer’s instructions, with recovered RNA quantified on a Nanodrop spectrophotometer. Equal amounts of total RNA were transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen, Manchester, U.K.) as per manufacturer’s instructions. Target gene expression was analysed using Quantifast SYBR Green Master Mix (Fisher Scientific) on a 7500 Fast Real-Time PCR System (Applied Biosystems, CA, U.SA.). The expression level of each gene was calculated using the ΔCt method and normalized against levels of L19 housekeeping gene. Primer sequences used were: PRL sense 5’-AAG CTG TAG AGA TTG AGG AGC AAA C-3’, PRL antisense 5’-TCA GGA TGA ACC TGG CTG ACT A-3’, IGFBP1 sense 5’-CGA AGG CTC TCC ATG TCA CCA-3’, IGFBP1 antisense 5’-TGT CTC CTG TGC CTT GGC TAA AC-3’, IL1RL1 sense 5’-TTG TCC TAC CAT TGA CCT CTA CAA-3’, IL1RL1 antisense 5’-GAT CCT TGA AGA GCC TGA CAA-3’, CLU sense 5’-GGG ACC AGA CGG TCT CAG-3’, CLU antisense 5’-CGT ACT TAC TTC CCT GAT TGG AC-3’; L19 sense 5’-GCG GAA GGG TAC AGC CAA-3’, L19 antisense 5’-GCA GCC GGC GCA AA-3’.
ELISA
Supernatant from cell cultures was collected every 2 days and cleared of cellular debris by centrifugation (275×g, 5 min, RT) before storage at −20 °C. Levels of secreted IGFBP1, prolactin, clusterin and soluble ST2 (sST2) in culture supernatant were quantified using DuoSet ELISA kits (Biotechne, MN, U.S.A.) as per manufacturer’s instructions. Absorbance at 450 nm was determined on a PHERAstar FS plate reader and concentrations were interpolated using a 4-parameter fit in GraphPad Prism (v9.0).
Statistical analysis
GraphPad Prism v9.0 (GraphPad Software Inc. CA, U.S.A.) was used for statistical analyses with data presented as fold-change relative to the most informative comparator. Paired Student’s t-test was performed to determine statistical significance between 2 groups, and one-way ANOVA, followed by Tukey’s or Dunnett’s post-hoc test for multiple comparisons involving more than 2 groups. Data with 2 independent variables was analysed using a two-way ANOVA (mixed methods) and Dunnett’s multiple comparison test using the most appropriate control as the comparator. In all cases, P < 0.05 was considered significant.
Data availability
The authors declare that all data supporting the findings of this study are available within the article and its supplementary information files. The datasets analysed during the current study are available in the Gene Expression Omnibus (GEO) repository GEO accession numbers GSE6510279, GSE10472180, GSE1279184 and GSE15926681. These were derived from the following public domain resource: https://www.ncbi.nlm.nih.gov/geo.
References
Casarini, L., Santi, D., Brigante, G. & Simoni, M. Two hormones for one receptor: Evolution, biochemistry, actions, and pathophysiology of LH and hCG. Endocr. Rev. 39, 549–592. https://doi.org/10.1210/er.2018-00065 (2018).
Fournier, T., Guibourdenche, J. & Evain-Brion, D. Review: hCGs: Different sources of production, different glycoforms and functions. Placenta 36, S60–S65. https://doi.org/10.1016/j.placenta.2015.02.002 (2015).
Gellersen, B. & Brosens, J. J. Cyclic decidualization of the human endometrium in reproductive health and failure. Endocr. Rev. 35, 851–905. https://doi.org/10.1210/er.2014-1045 (2014).
Lucas, E. S. et al. Recurrent pregnancy loss is associated with a pro-senescent decidual response during the peri-implantation window. Commun. Biol. 3, 37. https://doi.org/10.1038/s42003-020-0763-1 (2020).
Brighton, P. J. et al. Clearance of senescent decidual cells by uterine natural killer cells in cycling human endometrium. eLife https://doi.org/10.7554/eLife.31274 (2017).
Critchley, H. O. D., Maybin, J. A., Armstrong, G. M. & Williams, A. R. W. Physiology of the endometrium and regulation of menstruation. Physiol. Rev. 100, 1149–1179. https://doi.org/10.1152/physrev.00031.2019 (2020).
Ewington, L. J., Tewary, S. & Brosens, J. J. New insights into the mechanisms underlying recurrent pregnancy loss. J. Obstet. Gynaecol. Res. 45, 258–265. https://doi.org/10.1111/jog.13837 (2019).
Haig, D. Cooperation and conflict in human pregnancy. Curr. Biol. 29, R455–R458. https://doi.org/10.1016/j.cub.2019.04.040 (2019).
Kong, C. S. et al. Embryo biosensing by uterine natural killer cells determines endometrial fate decisions at implantation. FASEB J. 35, e21336. https://doi.org/10.1096/fj.202002217R (2021).
Brosens, J. J. et al. Uterine selection of human embryos at implantation. Sci. Rep. https://doi.org/10.1038/srep03894 (2014).
Ascoli, M., Fanelli, F. & Segaloff, D. L. The lutropin/choriocrctnadotropin receptor, a 2002 perspective. Endocr. Rev. 23, 141–174. https://doi.org/10.1210/er.23.2.141 (2002).
Xie, Y. B., Wang, H. Y. & Segaloff, D. L. Extracellular domain of lutropin choriogonadotropin receptor expressed in transfeced cells binds choriogonadotropin with high-affinity. J. Biol. Chem. 265, 21411–21414 (1990).
Choi, J. & Smitz, J. Luteinizing hormone and human chorionic gonadotropin: Origins of difference. Mol. Cell. Endocrinol. 383, 203–213. https://doi.org/10.1016/j.mce.2013.12.009 (2014).
Breen, S. M. et al. Ovulation involves the luteinizing hormone-dependent activation of G(q/11) in granulosa cells. Mol. Endocrinol. 27, 1483–1491. https://doi.org/10.1210/me.2013-1130 (2013).
Gilchrist, R. L., Ryu, K. S., Ji, I. H. & Ji, T. H. The luteinizing hormone chorionic gonadotropin receptor has distinct transmembrane conductors for cAMP and inositol phosphate signals. J. Biol. Chem. 271, 19283–19287. https://doi.org/10.1074/jbc.271.32.19283 (1996).
Han, S. W., Lei, Z. M. & Rao, C. V. Treatment of human endometrial stromal cells with chorionic gonadotropin promotes their morphological and functional differentiation into decidua. Mol. Cell. Endocrinol. 147, 7–16. https://doi.org/10.1016/s0303-7207(98)00240-8 (1999).
Licht, P., von Wolff, M., Berkholz, A. & Wildt, L. Evidence for cycle-dependent expression of full-length human chorionic gonadotropin/luteinizing hormone receptor mRNA in human endometrium and decidua. Fertil. Steril. 79, 718–723. https://doi.org/10.1016/s0015-0282(02)04822-7 (2003).
Srisuparp, S. et al. Signal transduction pathways activated by chorionic gonadotropin in the primate endometrial epithelial cells. Biol. Reprod. 68, 457–464. https://doi.org/10.1095/biolreprod.102.007625 (2003).
Perrier d’Hauterive, S. et al. Human chorionic gonadotropin and growth factors at the embryonic-endometrial interface control leukemia inhibitory factor (LIF) and interleukin 6 (IL-6) secretion by human endometrial epithelium. Hum. Reprod. 19, 2633–2643. https://doi.org/10.1093/humrep/deh450 (2004).
Banerjee, P., Sapru, K., Strakova, Z. & Fazleabas, A. T. Chorionic gonadotropin regulates prostaglandin E synthase via a phosphatidylinositol 3-kinase-extracellular regulatory kinase pathway in a human endometrial epithelial cell line: Implications for endometrial responses for embryo implantation. Endocrinology 150, 4326–4337. https://doi.org/10.1210/en.2009-0394 (2009).
Evans, J. & Salamonsen, L. A. Too much of a good thing? Experimental evidence suggests prolonged exposure to hCG is detrimental to endometrial receptivity. Hum. Reprod. 28, 1610–1619. https://doi.org/10.1093/humrep/det055 (2013).
Bernardini, L., Moretti-Rojas, I., Brush, M., Rojas, F. & Balmaceda, J. Failure of hCG/LH receptors to stimulate the transmembrane effector adenylyl cyclase in human endometrium. Adv. Biosci. Biotechnol. 4, 949. https://doi.org/10.4236/abb.2013.410126 (2013).
Tapia-Pizarro, A. et al. hCG activates Epac-Erk1/2 signaling regulating Progesterone Receptor expression and function in human endometrial stromal cells. Mol. Hum. Reprod. 23, 393–405. https://doi.org/10.1093/molehr/gax015 (2017).
Sacchi, S., Sena, P., Degli Esposti, C., Lui, J. & La Marca, A. Evidence for expression and functionality of FSH and LH/hCG receptors in human endometrium. J. Assist. Reprod. Genet. 35, 1703–1712. https://doi.org/10.1007/s10815-018-1248-8 (2018).
Pakarainen, T. et al. Extragonadal LH/hCG action: Not yet time to rewrite textbooks. Mol. Cell. Endocrinol. 269, 9–16. https://doi.org/10.1016/j.mce.2006.10.019 (2007).
Madhra, M., Gay, E., Fraser, H. M. & Duncan, W. C. Alternative splicing of the human luteal LH receptor during luteolysis and maternal recognition of pregnancy. Mol. Hum. Reprod. 10, 599–603. https://doi.org/10.1093/molehr/gah076 (2004).
Minegishi, T. et al. Expression of luteinizing hormone human chorionic gonadotrophin (LH/HCG) receptor mRNA in the human ovary. Mol. Hum. Reprod. 3, 101–107. https://doi.org/10.1093/molehr/3.2.101 (1997).
Stewart, E. A., Sahakian, M., Rhoades, A., Van Voorhis, B. J. & Nowak, R. A. Messenger ribonucleic acid for the gonadal luteinizing hormone human chorionic gonadotropin receptor is not present in human endometrium. Fertil. Steril. 71, 368–372. https://doi.org/10.1016/s0015-0282(98)00453-1 (1999).
Chrusciel, M., Ponikwicka-Tyszko, D., Wolczynski, S., Huhtaniemi, I. & Rahman, N. A. Extragonadal FSHR expression and function-is it real?. Front. Endocrinol. https://doi.org/10.3389/fendo.2019.00032 (2019).
Tang, B. Q. & Gurpide, E. Direct effect of gonadotropins on decidualization of human endometrial stromal cells. J. Steroid Biochem. Mol. Biol. 47, 115–121. https://doi.org/10.1016/0960-0760(93)90064-4 (1993).
Chatterjee, A., Jana, N. R. & Bhattacharya, S. Stimulation of cyclic AMP, 17 beta-oestradiol and protein synthesis by human chorionic gonadotrophin in human endometrial cells. Hum. Reprod. 12, 1903–1908. https://doi.org/10.1093/humrep/12.9.1903 (1997).
Kasahara, K. et al. The role of human chorionic gonadotropin on decidualization of endometrial stromal cells in vitro. J. Clin. Endocrinol. Metab. 86, 1281–1286. https://doi.org/10.1210/jc.86.3.1281 (2001).
Kajihara, T. et al. Human chorionic gonadotropin confers resistance to oxidative stress-induced apoptosis in decidualizing human endometrial stromal cells. Fertil. Steril. 95, 1302–1307. https://doi.org/10.1016/j.fertnstert.2010.05.048 (2011).
Macosko, E. Z. et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161, 1202–1214. https://doi.org/10.1016/j.cell.2015.05.002 (2015).
Garcia-Alonso, L. et al. Mapping the temporal and spatial dynamics of the human endometrium in vivo and in vitro. Nat. Genet. 53, 1698. https://doi.org/10.1038/s41588-021-00972-2 (2021).
Kosaka, K. et al. Human chorionic gonadotropin (HCG) activates monocytes to produce interleukin-8 via a different pathway from luteinizing hormone/HCG receptor system. J. Clin. Endocrinol. Metab. 87, 5199–5208. https://doi.org/10.1210/jc.2002-020341 (2002).
Simpson, D. Z., Hitchen, P. G., Elmhirst, E. L. & Taylor, M. E. Multiple interactions between pituitary hormones and the mannose receptor. Biochem. J. 343, 403–411. https://doi.org/10.1042/0264-6021:3430403 (1999).
Kane, N., Kelly, R., Saunders, P. T. K. & Critchley, H. O. D. Proliferation of uterine natural killer cells is induced by human chorionic gonadotropin and mediated via the mannose receptor. Endocrinology 150, 2882–2888. https://doi.org/10.1210/en.2008-1309 (2009).
Mi, Y. L., Lin, A., Fiete, D., Steirer, L. & Baenziger, J. U. Modulation of mannose and asialoglycoprotein receptor expression determines glycoprotein hormone half-life at critical points in the reproductive cycle. J. Biol. Chem. 289, 12157–12167. https://doi.org/10.1074/jbc.M113.544973 (2014).
Ku, S. Y. et al. Effect of gonadotropins on human endometrial stromal cell proliferation in vitro. Arch. Gynecol. Obstet. 266, 223–228. https://doi.org/10.1007/s00404-002-0292-9 (2002).
Jasinska, A., Strakova, Z., Szmidt, M. & Fazleabas, A. T. Human chorionic gonadotropin and decidualization in vitro inhibits cytochalasin-D-induced apoptosis in cultured endometrial stromal fibroblasts. Endocrinology 147, 4112–4121. https://doi.org/10.1210/en.2005-1577 (2006).
Licht, P., Russu, V. & Wildt, L. On the role of human chorionic gonadotropin (hCC) in the embryo-endometrial microenvironment: Implications for differentiation and implantation. Semin. Reprod. Med. 19, 37–47. https://doi.org/10.1055/s-2001-13909 (2001).
Sherwin, J. R. A. et al. Identification of novel genes regulated by chorionic gonadotropin in baboon endometrium during the window of implantation. Endocrinology 148, 618–626. https://doi.org/10.1210/en.2006-0832 (2007).
Mika, K. et al. Evolutionary transcriptomics implicates new genes and pathways in human pregnancy and adverse pregnacy outcomes. eLIFE 10, e69584. https://doi.org/10.7554/eLife.69584 (2021).
Wagner, G. P., Kin, K. & Lynch, V. J. Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory Biosci. 131, 281–285. https://doi.org/10.1007/s12064-012-0162-3 (2012).
Wagner, G. P., Kin, K. & Lynch, V. J. A model based criterion for gene expression calls using RNA-seq data. Theory Biosci. 132, 159–164. https://doi.org/10.1007/s12064-013-0178-3 (2013).
Kaur, H. et al. Single-cell profiling reveals heterogeneity and functional patterning of GPCR expression in the vascular system. Nat. Commun. 10, 15700. https://doi.org/10.1038/s41467-019-09334-3 (2019).
Tischner, D. et al. Single-cell profiling reveals GPCR heterogeneity and functional patterning during neuroinflammation. JCI Insight 2, e95063. https://doi.org/10.1172/jci.insight.95063 (2017).
Menon, K. M. J., Munshi, U. M., Clouser, C. L. & Nair, A. K. Regulation of luteinizing hormone/human chorionic gonadotropin receptor expression: A perspective. Biol. Reprod. 70, 861–866. https://doi.org/10.1095/biolreprod.103.024471 (2004).
Tao, Y. X., Johnson, N. B. & Segaloff, D. L. Constitutive and agonist-dependent self-association of the cell surface human lutropin receptor. J. Biol. Chem. 279, 5904–5914. https://doi.org/10.1074/jbc.M311162200 (2004).
Lei, Y. et al. Constitutively-active human LH receptors are self-associated and located in rafts. Mol. Cell. Endocrinol. 260, 65–72. https://doi.org/10.1016/j.mce.2005.11.046 (2007).
Roess, D. A., Horvat, R. D., Munnelly, H. & Barisas, B. G. Luteinizing hormone receptors are self-associated in the plasma membrane. Endocrinology 141, 4518–4523. https://doi.org/10.1210/en.141.12.4518 (2000).
Horvat, R. D. & Roess, D. A. Desensitized LH receptors are self-associated in large, slowly diffusing complexes. Biol. Reprod. 62, 106–106 (2000).
Smith, S. M. L. et al. Luteinizing hormone receptors translocate to plasma membrane microdomains after binding of human chorionic gonadotropin. Endocrinology 147, 1789–1795. https://doi.org/10.1210/en.2005-1046 (2006).
Zhang, M. L., Feng, X. Y., Guan, R. B., Hebert, T. E. & Segaloff, D. L. A cell surface inactive mutant of the human lutropin receptor (hLHR) attenuates signaling of wild-type or constitutively active receptors via heterodimerization. Cell. Signal. 21, 1663–1671. https://doi.org/10.1016/j.cellsig.2009.07.003 (2009).
Feng, X. Y., Zhang, M. L., Guan, R. B. & Segaloff, D. L. Heterodimerization between the lutropin and follitropin receptors is associated with an attenuation of hormone-dependent signaling. Endocrinology 154, 3925–3930. https://doi.org/10.1210/en.2013-1407 (2013).
Zhu, X., Gilbert, S., Birnbaumer, M. & Birnbaumer, L. Dual signaling potential is common among g(s)-coupled receptors and dependent on receptor density. Mol. Pharmacol. 46, 460–469 (1994).
Donadeu, F. X. & Ascoli, M. The differential effects of the gonadotropin receptors on aromatase expression in primary cultures of immature rat granulosa cells are highly dependent on the density of receptors expressed and the activation of the inositol phosphate cascade. Endocrinology 146, 3907–3916. https://doi.org/10.1210/en.2005-0403 (2005).
Casarini, L., Reiter, E. & Simoni, M. beta-arrestins regulate gonadotropin receptor-mediated cell proliferation and apoptosis by controlling different FSHR or LHCGR intracellular signaling in the hGL5 cell line. Mol. Cell. Endocrinol. 437, 11–21. https://doi.org/10.1016/j.mce.2016.08.005 (2016).
Gilioli, L., Marino, M., Simon, M. & Cassarini, L. The regulation of LHCGR-dependent signaling is linked to circadian gene expression. Endocr. Abstracts 49, EP1131 (2017).
Kishi, H., Kitahara, Y., Imai, F., Nakao, K. & Suwa, H. Expression of the gonadotropin receptors during follicular development. Reprod. Med. Biol. 17, 11–19. https://doi.org/10.1002/rmb2.12075 (2018).
Nair, A. K., Kash, J. C., Peegel, H. & Menon, K. M. J. Post-transcriptional regulation of luteinizing hormone receptor mRNA in the ovary by a novel mRNA-binding protein. J. Biol. Chem. 277, 21468–21473. https://doi.org/10.1074/jbc.M111653200 (2002).
Kash, J. C. & Menon, K. M. J. Identification of a hormonally regulated luteinizing hormone human chorionic gonadotropin receptor mRNA binding protein: Increased mRNA binding during receptor down-regulation. J. Biol. Chem. 273, 10658–10664. https://doi.org/10.1074/jbc.273.17.10658 (1998).
Sposini, S. & Hanyaloglu, A. C. Driving gonadotrophin hormone receptor signalling: The role of membrane trafficking. Reproduction 156, R195–R208. https://doi.org/10.1530/rep-18-0423 (2018).
Johnson, G. P. & Jonas, K. C. Mechanistic insight into how gonadotropin hormone receptor complexes direct signaling†. Biol. Reprod. 102, 773–783. https://doi.org/10.1093/biolre/ioz228 (2019).
Fiddes, J. C. & Goodman, H. M. The cDNA for the beta-subunit of human chorionic-gonadotropin suggests evolution of a gene by readthrough into the 3’-untranslated region. Nature 286, 684–687. https://doi.org/10.1038/286684a0 (1980).
Maston, G. A. & Ruvolo, M. Chorionic gonadotropin has a recent origin within primates and an evolutionary history of selection. Mol. Biol. Evol. 19, 320–335. https://doi.org/10.1093/oxfordjournals.molbev.a004085 (2002).
Riccetti, L. et al. Human luteinizing hormone and chorionic gonadotropin display biased agonism at the LH and LH/CG receptors. Sci. Rep. https://doi.org/10.1038/s41598-017-01078-8 (2017).
Fournier, T. Human chorionic gonadotropin: Different glycoforms and biological activity depending on its source of production. Annales D Endocrinologie 77, 75–81. https://doi.org/10.1016/j.ando.2016.04.012 (2016).
Kovalevskaya, G., Birken, S., Kakuma, T. & O’Connor, J. F. Early pregnancy human chorionic gonadotropin (hCG) isoforms measured by an immunometric assay for choriocarcinoma-like hCG. J. Endocrinol. 161, 99–106. https://doi.org/10.1677/joe.0.1610099 (1999).
Riccetti, L. et al. Heterogeneous hCG and hMG commercial preparations result in different intracellular signalling but induce a similar long-term progesterone response in vitro. Mol. Hum. Reprod. 23, 685–697. https://doi.org/10.1093/molehr/gax047 (2017).
Koistinen, H. et al. Hyperglycosylated hCG activates LH/hCG-receptor with lower activity than hCG. Mol. Cell. Endocrinol. 479, 103–109. https://doi.org/10.1016/j.mce.2018.09.006 (2019).
Kajihara, T. et al. Differential effects of urinary and recombinant chorionic gonadotropin on oxidative stress responses in decidualizing human endometrial stromal cells. Placenta 32, 592–597. https://doi.org/10.1016/j.placenta.2011.05.002 (2011).
Cole, L. A. hCG, five independent molecules. Clin. Chim. Acta 413, 48–65. https://doi.org/10.1016/j.cca.2011.09.037 (2012).
Schafer, A., Pauli, G., Friedmann, W. & Dudenhausen, J. W. Human choriogonadotropin (hCG) and placental-lactogen (HPL) inhibit interleukin-2 (IL-2) and increase interleukin-1-beta (IL-1-beta), interleukin-6 (IL-6) and tumor-necrosis-factor (TNF-alpha) expression in monocyte cell-cultures. J. Perinat. Med. 20, 233–240. https://doi.org/10.1515/jpme.1992.20.3.233 (1992).
Yousefi, S. et al. The effect of gonadotropins on the production of human interferon-gamma by mononuclear-cells. J. Interferon Res. 13, 213–220. https://doi.org/10.1089/jir.1993.13.213 (1993).
Komorowski, J., Gradowski, G. & Stepien, H. Effects of hCG and beta-hCG on IL-2 and sIL-2R secretion from human peripheral blood mononuclear cells: A dose-response study in vitro. Immunol. Lett. 59, 29–33. https://doi.org/10.1016/s0165-2478(97)00096-5 (1997).
McCoy, D. E. & Haig, D. Embryo selection and mate choice: Can ‘honest signals’ be trusted?. Trends Ecol. Evol. 35, 308–318. https://doi.org/10.1016/j.tree.2019.12.002 (2020).
Lucas, E. S. et al. Loss of endometrial plasticity in recurrent pregnancy loss. Stem Cells 34, 346–356. https://doi.org/10.1002/stem.2222 (2016).
Muter, J. et al. The glycosyltransferase EOGT regulates adropin expression in decidualizing human endometrium. Endocrinology 159, 994–1004. https://doi.org/10.1210/en.2017-03064 (2018).
Diniz-da-Costa, M. et al. Characterization of highly proliferative decidual precursor cells during the window of implantation in human endometrium. Stem Cells 39, 1067–1080. https://doi.org/10.1002/stem.3367 (2021).
Megill, C. et al. cellxgene: A performant, scalable exploration platform for high dimensional sparse matrices. bioRxiv https://doi.org/10.1101/2021.04.05.438318 (2021).
Barros, F., Brosens, J. & Brighton, P. Isolation and primary culture of various cell types from whole human endometrial biopsies. Bio-Protocol 6, e2028. https://doi.org/10.21769/BioProtoc.2028 (2016).
Jean-Alphonse, F. et al. Spatially restricted G protein-coupled receptor activity via divergent endocytic compartments. J. Biol. Chem. 289, 3960–3977. https://doi.org/10.1074/jbc.M113.526350 (2014).
Han, S. W., Lei, Z. M. & Rao, C. V. Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin during the differentiation of human endometrial stromal cells into decidua. Endocrinology 137, 1791–1797. https://doi.org/10.1210/en.137.5.1791 (1996).
Han, S. W., Lei, Z. M. & Rao, C. V. Homologous down-regulation of luteinizing hormone chorionic gonadotropin receptors by increasing the degradation of receptor transcripts in human uterine endometrial stromal cells. Biol. Reprod. 57, 158–164. https://doi.org/10.1095/biolreprod57.1.158 (1997).
Salker, M. et al. Natural selection of human embryos: Impaired decidualization of endometrium disables embryo-maternal interactions and causes recurrent pregnancy loss. PLoS ONE 5, e10287. https://doi.org/10.1371/journal.pone.0010287 (2010).
Fluhr, H. et al. Human chorionic gonadotropin inhibits insulin-like growth factor-binding protein-1 and prolactin in decidualized human endometrial stromal cells. Fertil. Steril. 86, 236–238. https://doi.org/10.1016/j.fertnstert.2005.12.031 (2006).
Berndt, S. et al. Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium. FASEB J. 20, 2630. https://doi.org/10.1096/fj.06-5885fje (2006).
Paiva, P. et al. Human chorionic gonadotrophin regulates FGF2 and other cytokines produced by human endometrial epithelial cells, providing a mechanism for enhancing endometrial receptivity. Hum. Reprod. 26, 1153–1162. https://doi.org/10.1093/humrep/der027 (2011).
Acknowledgements
The authors are indebted to all the women who participated in this study and generously donated endometrial biopsies for research. We are also grateful to those who facilitated their participation including Professor Siobhan Quenby, Dr Joshua Odendaal and Dr Amelia Hawkes. This work was supported by a UKRI BBSRC Award to Dr Aylin Hanyaloglu (BB/S001565/1) and by funds from the Tommy’s National Miscarriage Research Centre and Wellcome Trust Investigator Award to Professor Jan Brosens (212233/Z/18/Z).
Author information
Authors and Affiliations
Contributions
A.H. and J.B. acquired funding; P.B., A.H. and J.B. conceived and designed the study; P.B. and C.K. performed the experiments and analysed the data; P.B. and E.S. conducted the in silico analysis; O.M. performed the literature review for Tables 1 and 2. A.H. and J.B. acquired the cell lines and biological material for research; P.B. prepared the initial manuscript draft and all authors contributed to the text of the manuscript and reviewed the final submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Mann, O.N., Kong, CS., Lucas, E.S. et al. Expression and function of the luteinizing hormone choriogonadotropin receptor in human endometrial stromal cells. Sci Rep 12, 8624 (2022). https://doi.org/10.1038/s41598-022-12495-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-022-12495-9